ABBOTT LABORATORIES Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent
ABBOTT LABORATORIES (ABT) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent of -$29.00 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-01.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParent · last filed 2019-05-01
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for the quarter ending 2019-03-31 was -$29.00M.
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for the quarter ending 2018-12-31 was $15.00M, a 150.00% increase year-over-year.
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for the quarter ending 2018-09-30 was $35.00M.
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for the quarter ending 2018-06-30 was $118.00M.
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for fiscal 2018 was $136.00M.
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for fiscal 2017 was -$134.00M.
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for fiscal 2016 was -$15.00M.
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for fiscal 2015 was -$35.00M, a 137.23% decline from fiscal 2014.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2019-03-31 | -$29.00M 10-Q · filed 2019-05-01 | -$14.00M derived: sum of 2 quarters · filed 2019-05-01 | $21.00M derived: sum of 3 quarters · filed 2019-05-01 | $139.00M derived: sum of 4 quarters · filed 2019-05-01 |
| 2018-12-31 | $15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $50.00M derived: sum of 2 quarters · filed 2019-02-22 | $168.00M derived: sum of 3 quarters · filed 2019-02-22 | $136.00M 10-K · filed 2019-02-22 |
| 2018-09-30 | $35.00M 10-Q · filed 2018-10-31 | $153.00M derived: sum of 2 quarters · filed 2018-10-31 | $121.00M 10-Q · filed 2018-10-31 | $127.00M derived: sum of 4 quarters · filed 2019-05-01 |
| 2018-06-30 | $118.00M 10-Q · filed 2018-08-01 | $86.00M 10-Q · filed 2018-08-01 | $92.00M derived: sum of 3 quarters · filed 2019-05-01 | $54.00M derived: sum of 4 quarters · filed 2019-05-01 |
| 2018-03-31 | -$32.00M 10-Q · filed 2019-05-01 | -$26.00M derived: sum of 2 quarters · filed 2019-05-01 | -$64.00M derived: sum of 3 quarters · filed 2019-05-01 | -$101.00M derived: sum of 4 quarters · filed 2019-05-01 |
| 2017-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | -$32.00M derived: sum of 2 quarters · filed 2019-02-22 | -$69.00M derived: sum of 3 quarters · filed 2019-02-22 | -$134.00M 10-K · filed 2019-02-22 |
| 2017-09-30 | -$38.00M 10-Q · filed 2018-10-31 | -$75.00M derived: sum of 2 quarters · filed 2018-10-31 | -$140.00M 10-Q · filed 2018-10-31 | -$31.00M derived: sum of 4 quarters · filed 2019-02-22 |
| 2017-06-30 | -$37.00M 10-Q · filed 2018-08-01 | -$102.00M 10-Q · filed 2018-08-01 | $7.00M derived: sum of 3 quarters · filed 2019-02-22 | -$20.00M derived: sum of 4 quarters · filed 2019-02-22 |
| 2017-03-31 | -$65.00M 10-Q · filed 2018-05-02 | $44.00M derived: sum of 2 quarters · filed 2019-02-22 | $17.00M derived: sum of 3 quarters · filed 2019-02-22 | $9.00M derived: sum of 4 quarters · filed 2019-02-22 |
| 2016-12-31 | $109.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $82.00M derived: sum of 2 quarters · filed 2019-02-22 | $74.00M derived: sum of 3 quarters · filed 2019-02-22 | -$15.00M 10-K · filed 2019-02-22 |
| 2016-09-30 | -$27.00M 10-Q · filed 2017-11-02 | -$35.00M derived: sum of 2 quarters · filed 2017-11-02 | -$124.00M 10-Q · filed 2017-11-02 | |
| 2016-06-30 | -$8.00M 10-Q · filed 2017-08-02 | -$97.00M 10-Q · filed 2017-08-02 | ||
| 2016-03-31 | -$89.00M 10-Q · filed 2017-05-03 | |||
| 2015-12-31 | -$35.00M 10-K · filed 2018-02-16 | |||
| 2014-12-31 | $94.00M 10-K · filed 2017-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |